Status:

COMPLETED

Study Evaluating PD-0299685 for the Treatment of Vasomotor Symptoms (Hot Flashes / Flushes) Associated With Menopause

Lead Sponsor:

Pfizer

Conditions:

Hot Flashes

Eligibility:

FEMALE

40-70 years

Phase:

PHASE2

Brief Summary

The primary purpose of this study is to determine if PD-0299685 is effective and safe in the treatment of vasomotor symptoms (hot flashes / flushes) associated with menopause.

Eligibility Criteria

Inclusion

  • Postmenopausal as defined by 6 months of spontaneous amenorrhea with serum FSH levels \>40mlU/ml and estradiol \< than = 25 pg/mL or 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy and FSH levels \> 40 mlU/ml and estradiol \< than = 25 pg/mL
  • Women reporting at least 50 moderate to severe vasomotor symptoms per week, recorded for seven consecutive days
  • Aged 40 to 70 years

Exclusion

  • No estrogen monotherapy or estrogen/progesterone containing drug products within applicable wash out period prior to screening
  • Use of SERMs, clonidine within 4 weeks of screening
  • Use of CNS active medication within 1 week of screening
  • Use of medications (SSRI; SNRI), herbal or dietary supplements, including black cohosh, soy, phytoestrogens or over the counter agent known to possibly be effective for the treatment of vasomotor symptoms, within 4 weeks of screening
  • Participation in clinical trial within 30 days
  • Significant medical or psychiatric illness within past 12 months

Key Trial Info

Start Date :

August 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

July 1 2007

Estimated Enrollment :

527 Patients enrolled

Trial Details

Trial ID

NCT00314964

Start Date

August 1 2006

End Date

July 1 2007

Last Update

March 16 2011

Active Locations (80)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 20 (80 locations)

1

Pfizer Investigational Site

Phoenix, Arizona, United States, 85015

2

Pfizer Investigational Site

Phoenix, Arizona, United States, 85032

3

Pfizer Investigational Site

Tucson, Arizona, United States, 85704

4

Pfizer Investigational Site

Tucson, Arizona, United States, 85741